News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Elixir Pharmaceuticals And Siena Biotech S.p.A. Enter Agreement To Evaluate SIRT1 Inhibitors In Huntington's Disease



2/13/2007 9:51:56 AM

CAMBRIDGE, Mass. & SIENA, Italy--(BUSINESS WIRE)--Elixir Pharmaceuticals, Inc. and Siena Biotech S.p.A. announced today that the two companies have entered into an agreement to collaborate on the optimization, validation and evaluation of Elixir’s SIRT1 inhibitors in Huntington’s disease. Huntington’s disease is a hereditary, degenerative brain disorder for which there is no present effective treatment or cure.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES